JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Aims to achieve CDMO sales of US$ 400 million by 2028
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Subscribe To Our Newsletter & Stay Updated